Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan 1;37(1):131-149.
doi: 10.1681/ASN.0000000779. Epub 2025 Jul 9.

Identification of Renal Transcripts Associated with Kidney Function and Prognosis in ANCA-Associated Vasculitis

Benoît Brilland  1   2   3 , Jérémie Riou  4 , Thomas Quéméneur  5 , Cyrille Vandenbussche  5 , Nathalie Merillon  2   6 , Andrea Boizard-Moracchini  7 , Maëva Roy  7 , Maïa Despré  2 , Giorgina Barbara Piccoli  8 , Assia Djema  9 , Nicolas Henry  10 , Laurence Preisser  2 , Odile Blanchet  2   11 , Viviane Gnemmi  12 , Marie-Christine Copin  2   13 , David Langlais  3 , Pascale Jeannin  2   7 , Patrick Blanco  7   14 , Yves Delneste  2   7 , Jean-François Augusto  1   2 ; Maine-Anjou Registry Research Group
Collaborators, Affiliations

Identification of Renal Transcripts Associated with Kidney Function and Prognosis in ANCA-Associated Vasculitis

Benoît Brilland et al. J Am Soc Nephrol. .

Abstract

Key Points:

  1. Large-scale kidney transcriptomics identifies a 12-gene signature, including CLU and C3, predicting kidney failure in ANCA-associated vasculitis.

  2. This molecular signature outperformed Berden, renal risk score, and ANCA kidney risk score clinicopathologic classifications.

  3. ANCA-associated vasculitis with GN kidneys show broad immune dysregulation, notably in complement, TGFβ, and immunometabolism pathways.

Background: ANCA-associated vasculitis with GN (AAV-GN) frequently progresses to kidney failure. However, tools for risk stratification of kidney outcomes remain limited. Existing approaches inadequately capture the molecular complexity underlying kidney injury, despite its potential value to tailor therapeutic management. We explored whether kidney transcriptomics could identify molecular signatures linked to kidney outcomes.

Methods: We included 199 patients with AAV-GN from two multicenter biobanks, and 23 controls. Kidney biopsies were profiled using NanoString nCounter to assess the expression of 750 immune-related genes. We conducted differential gene expression analysis, pathway enrichment analysis, and immune cell infiltration estimation to explore associations with kidney function and survival. A 12-gene prognostic signature was developed through least absolute shrinkage and selection operator–penalized Cox regression and compared with established histologic classifications (Berden classification, renal risk score, and ANCA kidney risk score) with robust internal validation.

Results: AAV-GN demonstrated extensive immune dysregulation with 150 differentially expressed genes versus controls, highlighting complement activation, immune cell recruitment and activation, TGFβ signaling, and immunometabolism pathways. Immune cell infiltration was marked by increased macrophages, dendritic cells, neutrophils, and T-cell subsets, reflecting broad immune activation. Initial eGFR correlated with the expression of 319 genes. A 12-gene signature (CLU, C3, LTF, FLT1, PLCG2, FES, PRKCD, TXNIP, SLC7A5, PTEN, NRBF2, and NFATC1) was significantly more strongly associated with kidney survival than were established histologic classifications (adjusted P value < 0.0001). Both high expression and low expression of several immune pathways (especially lymphocyte trafficking) were associated with better outcomes compared with intermediate expression.

Conclusions: Transcriptomic analysis of kidney biopsies in AAV-GN identified 150 differentially expressed immune-related genes and led to the development of a 12-gene signature that correlated strongly with kidney survival, outperforming established histologic classifications.

Trial registration: ClinicalTrials.gov NCT06388941.

Keywords: ANCA; GN; biomarkers; vasculitis.

PubMed Disclaimer

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/JSN/F315.

References

    1. Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol. 2017;12(10):1680–1691. doi: 10.2215/CJN.02500317 - DOI - PMC - PubMed
    1. Moiseev S, Novikov P, Jayne D, Mukhin N. End-stage renal disease in ANCA-associated vasculitis. Nephrol Dial Transplant. 2017;32(2):248–253. doi: 10.1093/ndt/gfw046 - DOI - PubMed
    1. Sinico RA, Di Toma L, Radice A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev. 2013;12(4):477–482. doi: 10.1016/j.autrev.2012.08.006 - DOI - PubMed
    1. de Joode AAE, Sanders JSF, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol. 2013;8(10):1709–1717. doi: 10.2215/CJN.01020113 - DOI - PMC - PubMed
    1. Flossmann O Berden A de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488–494. doi: 10.1136/ard.2010.137778 - DOI - PubMed

Associated data

LinkOut - more resources